This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Infant Aphakia Treatment Study (IATS) (IATS)

This study has been completed.
Sponsor:
Collaborators:
National Eye Institute (NEI)
Alcon Research
Bausch & Lomb Incorporated
BSN-JOBST Inc.
Eye Care and Cure
Information provided by (Responsible Party):
Scott R Lambert, MD, Emory University
ClinicalTrials.gov Identifier:
NCT00212134
First received: September 13, 2005
Last updated: July 27, 2016
Last verified: July 2016
Results First Received: July 15, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Congenital Cataract
Interventions: Device: hyperopic correction of infant surgical aphakia with Contact Lens
Device: primary implantation of aphakic intraocular lens

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment 12/23/04 to 01/16/09 at 12 medical clinics.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Final eligibility determined at pre-operative ocular examination under anesthesia.

Reporting Groups
  Description
Aphakic Contact Lens

optical correction of infant aphakia with aphakic Contact lens

INTERVENTION: aphakic contact lens

Aphakic Intraocular Lens

optical correction of infant aphakia with aphakic Intraocular Lens

INTERVENTION: aphakic intraocular lens


Participant Flow for 2 periods

Period 1:   Phase 1 (to Age 1 Year)
    Aphakic Contact Lens   Aphakic Intraocular Lens
STARTED   57   57 
Complete First Endpoint at 1 Year   57   57 
COMPLETED   57 [1]   57 [1] 
NOT COMPLETED   0   0 
[1] Age 1 data collection visit

Period 2:   Phase 2 (Age 1 Year to Age 5 Years)
    Aphakic Contact Lens   Aphakic Intraocular Lens
STARTED   57 [1]   57 [1] 
COMPLETED   57   56 [2] 
NOT COMPLETED   0   1 
[1] Visual acuity assessment at Age 4.5 Years and final visit at Age 5 Years.
[2] Patient lost to follow-up.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Aphakic Contact Lens

optical correction of infant aphakia with aphakic Contact lens

INTERVENTION: aphakic contact lens

Aphakic Intraocular Lens

optical correction of infant aphakia with aphakic Intraocular Lens

INTERVENTION: aphakic intraocular lens

Total Total of all reporting groups

Baseline Measures
   Aphakic Contact Lens   Aphakic Intraocular Lens   Total 
Overall Participants Analyzed 
[Units: Participants]
 57   57   114 
Age 
[Units: Months]
Mean (Standard Deviation)
     
mean/sd   2.4  (1.6)   2.5  (1.6)   2.5  (1.6) 
Age, Customized 
[Units: Participants]
     
28 - 48 days   25   25   50 
49 days - 3.0 months   17   15   32 
3.1 - 5.0 months   9   10   19 
5.1 - 6.8 months   6   7   13 
Gender 
[Units: Participants]
     
Female   32   28   60 
Male   25   29   54 
Ethnicity (NIH/OMB) 
[Units: Participants]
     
Hispanic or Latino   9   10   19 
Not Hispanic or Latino   48   47   95 
Unknown or Not Reported   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
     
American Indian or Alaska Native   1   0   1 
Asian   2   1   3 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   3   5   8 
White   49   48   97 
More than one race   0   3   3 
Unknown or Not Reported   2   0   2 
Region of Enrollment 
[Units: Participants]
     
United States   57   57   114 
Private Insurance 
[Units: Participants]
     
No   20   24   44 
Yes   37   33   70 
Qualified for Medicaid 
[Units: Participants]
     
No   40   35   75 
Yes   17   22   39 
Pupil Diameter - Cataractous Eye 
[Units: Mm]
Mean (Standard Deviation)
 3.3  (1.0)   3.2  (1.0)   3.3  (1.0) 
Pupil Diameter - Fellow Eye 
[Units: Mm]
Mean (Standard Deviation)
 3.5  (0.9)   3.4  (0.9)   3.4  (0.9) 
Corneal Diameter - Cataractous Eye 
[Units: Mm]
Mean (Standard Deviation)
 10.5  (0.7)   10.5  (0.8)   10.5  (0.7) 
Corneal Diameter - Fellow Eye 
[Units: Mm]
Mean (Standard Deviation)
 10.8  (0.6)   10.8  (0.7)   10.8  (0.6) 
Intraocular Pressure - Cataractous Eye 
[Units: mmHg]
Mean (Standard Deviation)
 12.7  (4.9)   11.8  (4.9)   12.2  (4.9) 
Intraocular Pressure - Fellow Eye 
[Units: mmHg]
Mean (Standard Deviation)
 12.8  (5.1)   12.9  (4.3)   12.9  (4.7) 
Keratometric Power - Cataractous Eye 
[Units: Diopters]
Mean (Standard Deviation)
 46.4  (2.7)   46.4  (2.7)   46.4  (2.7) 
Keratometric Power - Fellow Eye 
[Units: Diopters]
Mean (Standard Deviation)
 45.5  (1.8)   45.4  (1.9)   45.5  (1.8) 
Axial Length - Cataractous Eye 
[Units: Mm]
Mean (Standard Deviation)
 18.0  (1.3)   18.1  (1.3)   18.0  (1.3) 
Axial Length - Fellow Eye 
[Units: Mm]
Mean (Standard Deviation)
 18.4  (0.9)   18.7  (0.9)   18.6  (0.9) 
Refractive Error - Fellow Eye [1] 
[Units: Diopters]
Mean (Standard Deviation)
 2.4  (1.8)   2.3  (2.2)   2.3  (2.0) 
[1] Spherical equivalent of the refraction measured under cycloplegia


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Visual Acuity   [ Time Frame: Phase 1 - Age 12 months ]

2.  Primary:   Visual Acuity - Subjective Assessment at Age 4.5 Years.   [ Time Frame: Phase 2 - Age 4.5 Years ]

3.  Secondary:   Percent of Patients With 1 or More Intraoperative Complications at Cataract Surgery   [ Time Frame: Cataract surgery immediately after enrollment ]

4.  Secondary:   Percent of Patients With 1 or More Adverse Events   [ Time Frame: Study enrollment to age 5 years ]

5.  Secondary:   Parenting Stress   [ Time Frame: Phase 1 - 3 months post surgery ]

6.  Secondary:   Adherence to Occlusion Therapy   [ Time Frame: Phase 1 - 12 months follow-up ]

7.  Secondary:   Parenting Stress   [ Time Frame: Phase 1 - Age 12 Months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Scott R Lambert, MD, Study Chairman
Organization: Emory School of Medicine
phone: 404-778-3709
e-mail: slamber@emory.edu


Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Scott R Lambert, MD, Emory University
ClinicalTrials.gov Identifier: NCT00212134     History of Changes
Other Study ID Numbers: IRB00024837
U10EY013272 ( U.S. NIH Grant/Contract )
EY013287 ( Other Grant/Funding Number: Emory )
EY013272 ( Other Grant/Funding Number: Emory )
NEI-108 ( Other Identifier: Other )
Study First Received: September 13, 2005
Results First Received: July 15, 2013
Last Updated: July 27, 2016